Ibrutinib modulates CD19 expression and improves efficacy of CD19-CAR T cells in B-cell lymphoma models
Antigen density critically influences CAR T-cell efficacy. We show that ibrutinib induces CD19 upregulation in B-cell lymphoma models, enhancing CAR T-cell cytotoxicity. Pharmacologic modulation of target antigen expression represents a promising strategy to overcome resistance.
immunology↗